share_log

Soligenix Shares Are Trading Higher After the Company Announced Interim Data From Its Investigator-initiated Study of HyBryte for Early-stage Cutaneous T-cell Lymphoma, Which Showed Over 70% of Patients Who Completed at Least 18 Weeks of Therapy...

Benzinga ·  Jan 14 12:49

Soligenix Shares Are Trading Higher After the Company Announced Interim Data From Its Investigator-initiated Study of HyBryte for Early-stage Cutaneous T-cell Lymphoma, Which Showed Over 70% of Patients Who Completed at Least 18 Weeks of Therapy Achieved "Treatment Success."

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 431

Recommended

Write a comment